Biological agents and gemcitabine in the treatment of breast cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Morandi, Paolo ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Breast cancer; Gemcitabine; Targeted therapies

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; HYDROXYUREA; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SEPTIC SHOCK; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL FACTORS; BREAST NEOPLASMS; DEOXYCYTIDINE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBONUCLEOTIDE REDUCTASES;

EID: 33745624597     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj977     Document Type: Article

References (22)

1. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995 13: 2731-2736.
2. Blackstein M, Vogel CL, Ambinder R et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 2002 62: 2-8.
3. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
4. Graham DL, Hillman DW, Hobday TJ et al. N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2005; 23: (Abstr. 644).
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
6. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004 96(10): 739-49.
7. Konecny GE, Pegram MD. Gemcitabine in combination with trastuzumab and/ or platinum salts in breast cancer cells with HER2 overexpression Oncology (Williston Park) 2004 Dec; 18 (14 Suppl 12): 32-6.
8. O'Shaughnessy JA, Vukelja S, Marsland T et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004; 5(2): 142-7.
9. Christodoulou C, Fountzilas G, Razi E et al. Proc Am Soc Clin Oncol 2003; 22: 42 (Abstr. 166).
10. Fountzilas G, Christodouou C, Tsavaridis D et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest. 2004; 22(5): 655-62.
11. Sledge GW Jr. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 2003; 17 (12 Suppl 14): 33-5.
12. Miller K, Sisk J, Ansari R et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 2001 15 (2 suppl 3): 38-40.
13. Polyzos A, Mavroudis D, Boukovinas J et al. A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. Proc Am Soc Clin Oncol 2004 22: 5 (Abstr. 728).
14. Baselga J. Is circulating HER-2 more than just a tumor marker? Clin Cancer Res 2001;7: 2605-2607.
15. Colomer R, Lombart-Cussac A, Lluch A et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004; 15(2): 201-6.
16. Colomer R, Mayordomo JL, Calvo L et al Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22: 5 (Abstr. 740).
17. Miyakis S, Sourvinos G, Spandidos D. Differential expression and mutation of the Ras family genes in human breast cancer. Biochem Biophys Res Commun 1998; 251: 609-612.
18. Johnston SR, Kelland LR. Farnesyl transferase inhibitors: A novel therapy for breast cancer. Endocr Relat Cancer 2001; 8: 227-235.
19. Kelland LR, Smith V, Valenti M et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001; 7: 3544-3550.
20. Cory JG, Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem 1983; 53: 54257-266.
21. Murren J, Modiano M, Clairmont C et al. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase Inhibitor, Administered Daily for Five Days in Patients with Advanced Solid Tumors. Clin Cancer Res 2003; 9: 4092-4100.
22. Jordheim LP, Guittet O, Lepoivre M et al. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 2005; 4(8): 1268-76.